When it comes to early cancer detection in dogs, timing is everything. Most veterinary clinics still rely on traditional methods like palpation, fine needle aspiration (FNA), and biopsies — all of which take time, can be invasive, and often cause stress for both the dog and their owner.

Enter HT Vista: a revolutionary AI-powered veterinary diagnostic technology now available across Australia and New Zealand through Vet Edge's exclusive partnership with HT Vet International.

But how reliable is this advanced canine cancer screening really? We dove into the clinical data — and the results are worth sharing.

The Science Behind HT Vista's Cancer Detection Accuracy

At its core, HT Vista uses heat diffusion imaging for dogs combined with artificial intelligence to determine if a mass poses cancer risk. This non-invasive canine cancer screening technology represents a significant advancement in veterinary cancer detection capabilities.

HT Vista's Primary Classifier: Core Performance Metrics

The device's primary classifier determines if a mass is low or high cancer risk. Here's what the clinical data reveals:

90% Sensitivity for Cancer Detection HT Vista correctly identifies 9 out of 10 cancerous tumors — an impressive result for a non-surgical cancer screening tool. This high sensitivity means fewer dangerous cancers slip through initial screening.

98% Negative Predictive Value (NPV) When the device flags a mass as low risk, there's a 98% chance it truly is benign. That's peace of mind you can confidently communicate to concerned dog parents during lump and bump scanning.

70% Specificity The device occasionally flags benign tumors as higher risk — a deliberate design choice that prioritises patient safety. In cancer diagnosis for dogs, erring on the side of caution protects patient outcomes.

42% Positive Predictive Value (PPV) Not every "high risk" flag indicates cancer, which is why HT Vista serves as a screening tool that guides further diagnostics like FNA or histopathology rather than replacing them.

Lipoma Detection: Exceptional Accuracy for Common Benign Lumps

Lipomas are among the most common benign lumps in dogs, and HT Vista's heat diffusion technology excels at identifying them:

Clinical Performance for Lipoma Detection:

• 99% Positive Predictive Value: If HT Vista identifies a lipoma, it's almost certainly correct
• 90% Specificity: Very few non-lipomas get mistakenly flagged as lipomas
• 69% Sensitivity: May miss some lipomas (prioritising safety), but serves as an excellent filter for ruling out malignant vs benign lump detection

Clinical Impact: When a lump is flagged as a lipoma by HT Vista, veterinarians can confidently advise monitoring without immediately proceeding to invasive procedures — reducing stress and costs for dog families.

Mast Cell Tumor (MCT) Detection: High-Risk Cancer Identification

Mast Cell Tumors represent one of the most frequently diagnosed malignant skin tumors in dogs. HT Vista's specialised MCT subclassifier delivers:

MCT Detection Performance:

• 90% Specificity: Minimal false alarms for suspected MCTs
• 77% Positive Predictive Value: When flagged as MCT, the diagnosis is correct most of the time
• 44% Sensitivity: Some MCTs may require additional clinical assessment

While not perfect, HT Vista proves highly valuable for highlighting when urgent further diagnostics are essential for canine cancer screening.

Real-World Clinical Impact: Why Performance Data Matters

HT Vista doesn't replace veterinary expertise — it enhances clinical decision-making. As a screening tool rather than a definitive diagnostic, it empowers veterinarians to:

Streamline Patient Care

• Identify low-risk lumps in just 40 seconds without aspirates or biopsies
• Prioritise cases requiring immediate attention
• Reduce unnecessary invasive procedures for benign masses
• Build trust with dog parents through transparent, data-driven recommendations

Improve Practice Efficiency

• Nurse-led scanning capabilities free up veterinary time
• Immediate results eliminate waiting periods for external lab results
• Enhanced workflow for routine dog health monitoring

The Australian Advantage: Global Technology, Local Support

Backed by extensive clinical validation and used globally, HT Vista is now transforming veterinary practices across Australia and New Zealand. This affordable cancer detection for dogs solution helps clinics move from guesswork to evidence-based guidance, faster.

Vet Edge's comprehensive support ensures your practice maximises HT Vista's clinical performance through:

• Thorough team training on optimal scanning techniques
• Ongoing clinical interpretation support
• Integration guidance for seamless workflow adoption
• Marketing support to communicate value to dog owners

‍

Experience HT Vista's Performance in Your Practice

Curious how these impressive performance metrics could enhance your veterinary practice? The clinical data speaks for itself — but experiencing HT Vista's capabilities firsthand demonstrates its true value.

Book a demo with Vet Edge today and discover how this revolutionary canine cancer detection technology can transform your approach to lump and bump assessments.

‍HT Vista: Where clinical science meets practical veterinary care. Experience the difference that 90% sensitivity and 98% NPV makes in daily practice.

‍